title: Protein expressions and genetic variations of SLC5A8 in prostate cancer risk and aggressiveness.
abstract: OBJECTIVE
  To understand the role in prostate cancer risk and aggressiveness, we investigated the expression in prostate tumor and single nucleotide polymorphisms of SLC5A8. Previous studies have suggested that SLC5A8 might function as a tumor suppressor gene, whose silencing by epigenetic changes might contribute to carcinogenesis.
  
  
  METHODS
  We constructed tissue microarrays from 183 prostate tumor tissues, 43 adjacent non-neoplastic tissues from the same patients, and 13 tissue samples from patients with benign prostatic hyperplasia or prostatic intraepithelial neoplasia. A semiquantitative assessment of SLC5A8 protein expression was determined as the product of immunostaining intensity and the percentage of cells stained. In addition, we compared the frequencies of 4 single nucleotide polymorphisms (rs164365, rs1709189, rs1399236, and rs1681096) in SLC5A8 between 668 prostate cancer cases and 385 controls.
  
  
  RESULTS
  SLC5A8 expression was significantly greater in the tumor tissues than in the paired non-neoplastic tissues (P < .0001). In the Moffitt samples, we observed a borderline moderate risk increase in patients with a genotype containing ≥1 "A" allele of rs164365 (odds ratio 1.35, 95% confidence interval 1.00-1.80), especially among tall men (≥70 in.; odds ratio 1.80, 95% confidence interval 1.20-2.68). However, these results were not confirmed in the Cancer Genetic Markers of Susceptibility population.
  
  
  CONCLUSIONS
  These data suggest that the expression pattern of SLC5A8 might be used as a diagnostic biomarker, and a larger study is required to assess the importance of SLC5A8 single nucleotide polymorphisms in prostate cancer.
authors.affiliation: Department of Biostatistics, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
authors.forename: Hui-Yi
authors.initials: HY
authors.lastname: Lin
authors.forename: Hyun Y
authors.initials: HY
authors.lastname: Park
authors.forename: Selina
authors.initials: S
authors.lastname: Radlein
authors.forename: Nupam P
authors.initials: NP
authors.lastname: Mahajan
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Sellers
authors.forename: Babu
authors.initials: B
authors.lastname: Zachariah
authors.forename: Julio
authors.initials: J
authors.lastname: Pow-Sang
authors.forename: Domenico
authors.initials: D
authors.lastname: Coppola
authors.forename: Vadivel
authors.initials: V
authors.lastname: Ganapathy
authors.forename: Jong Y
authors.initials: JY
authors.lastname: Park
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D027682:Cation Transport Proteins / Q000096:biosynthesis* / Q000235:genetics*; D015331:Cohort Studies; D015972:Gene Expression Regulation, Neoplastic; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D027501:Monocarboxylic Acid Transporters; D009361:Neoplasm Invasiveness; D009369:Neoplasms / Q000235:genetics* / Q000378:metabolism; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000378:metabolism*; D012306:Risk
chemical_list: D027682:Cation Transport Proteins; D027501:Monocarboxylic Acid Transporters; C476760:SLC5A8 protein, human